Breast Cancer Therapeutics in Major Developed Markets to 2020
Albany, NY (PRWEB) June 03, 2014
"Breast Cancer Therapeutics in Major Developed Markets to 2020 – Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs", which provides in-depth analysis of breast cancer therapeutics market within the eight major geographies of the US, Canada, the top five geographies in Europe (the UK, France, Germany, Spain and Italy) and Japan. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.
The breast cancer therapeutics market in the eight major markets – The US, The UK, France, Germany, Spain, Italy, Japan and Canada – was worth $9.2 billion in 2013, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 5.1% to $13.1 billion by 2020. The US had the largest market in 2013, valued at $5.5 billion, equivalent to a global share of 59%, followed by Japan with $871.5m or 9.4% and Italy with $668.5m or 7.2%. Canada had the lowest market share and value of the leading eight at 2.9% and $268.4m, but is expected to witness rapid growth over the forecast period with a CAGR of 6.7%. This will only be surpassed by Japan, which is expected to witness growth at a CAGR of 6.9%.
View Full Breast Cancer Therapeutics Market Report With Complete TOC or Request Sample of This Report at http://www.researchmoz.us/breast-cancer-therapeutics-in-major-developed-markets-to-2020-approval-of-novel-therapies-to-support-continued-dominance-of-her2-targeted-drugs-report.html.
The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the breast cancer in the major developed markets.
The report includes:
Disease overview, as well as treatment algorithms and treatment usage patterns
Market size and forecast for the breast cancer market from 2012 to 2019
Major marketed products for breast cancer along with a heat map of product performance
In-depth pipeline analysis for global pipeline in breast cancer along with clinical trial failure rate analysis
Key drivers and restraints that have had and are expected to have a significant impact upon the market
Key licensing and co-development agreements that could have impact on growth trends
Reasons to Buy:
The report will enhance your decision-making capability by allowing you to:
Align your product portfolio to the markets with high growth potential
Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the breast cancer therapeutics market
Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
Anti-Hypertensive Therapeutics in Major Developed Markets to 2020 - Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries
The value of the hypertension market in the major developed markets amounted to an estimated $40.0 billion in 2013 and is expected to decline during the forecast period at a negative Compound Annual Growth Rate (CAGR) of 0.9% to $37.6 billion in 2020, with growth expected from 2013 to 2017 at a CAGR of 2.6% and a decline thereafter. The initial growth will be due to the increased penetration of fixed-dose combination drugs (Amturnide, Exforge Tribenzor, Azor, Tekturna HCT, Edarbyclor, Twynsta, Benicar HCT, Micardis Plus, Tekamlo, Valturna), a rise in the prevalence population from 181 million to 190 million at a CAGR of 0.6%, and two new expected launches in the pipeline (azilsartan + amlodipine, and AHU377+ valsartan). However, due to the expiry of the exclusivity of major drugs both before and during the forecast period (Cozaar in 2010; Diovan, Avapro and Atacand in 2012; Exforge in 2014; Benicar in 2016; and Tekturna and Tekturna HCT in 2018), increased generic penetration and a low diagnosis rate, the market will decline from 2017. Browse Full Report with TOC at: http://www.researchmoz.us/anti-hypertensive-therapeutics-in-major-developed-markets-to-2020-increased-uptake-of-combination-therapies-to-offset-effects-of-key-patent-expiries-report.html.
Market Snapshot: Glucose Monitoring Devices 2014 - Benelux and Scandinavia
“Glucose Monitoring Devices Market 2014 – Benelux and Scandinavia” provides quantitative analysis of the two glucose monitoring devices market segments: blood glucose meters and blood glucose test strips. The analysis includes market size data by revenue and volume over the 2006–2020 period and key company share data by revenue and volume in 2013 for the following countries: are Netherlands, Belgium, Luxembourg, Sweden, Denmark and Norway. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Browse Full Report with TOC at: http://www.researchmoz.us/market-snapshot-glucose-monitoring-devices-2014-benelux-and-scandinavia-report.html.
Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany
Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany”. Due to the poor prognosis under currently available treatments, therapies with high potency are in strong demand in the Glioblastoma Multiforme (GBM) market. In newly diagnosed patients, the current standard of care, comprising resection surgery, radiation therapy and chemotherapy with Merck’s Temodar (temozolomide), has a maximum Overall Survival (OS) of 15 months and almost inevitable tumor recurrence. Current therapeutic options for recurrent GBM are Roche’s Avastin (bevacizumab), carmustine and other chemotherapy drugs used off-label. However, they only offer limited OS benefit, leaving high unmet need in this patient segment. During the 2012–2019 forecast period, the GBM market is expected to grow rapidly from $305m to $583m. Browse Full Report with TOC at: http://www.researchmoz.us/glioblastoma-multiforme-therapeutics-in-major-developed-markets-to-2019-growth-to-hinge-on-the-success-of-personalized-vaccine-following-early-approval-in-germany-report.html.
ResearchMoz (http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. We provide the market context, competitor insight and future trends needed for strategic planning.
For More Information Kindly Contact:
Toll Free: 866-997-4948